<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0390</journal-id>
<journal-title><![CDATA[Revista Médica del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. Urug.]]></abbrev-journal-title>
<issn>1688-0390</issn>
<publisher>
<publisher-name><![CDATA[Sindicato Médico del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-03902025000101202</article-id>
<article-id pub-id-type="doi">10.29193/rmu.41.1.3</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación del voriconazol como profilaxis de infecciones fúngicas invasivas en receptores de trasplante alogénico de células progenitoras hematopoyéticas: experiencia de un centro en Uruguay]]></article-title>
<article-title xml:lang="en"><![CDATA[Evaluation of voriconazole as prophylaxis for invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplantation: experience from a center in Uruguay]]></article-title>
<article-title xml:lang="pt"><![CDATA[Avaliação do voriconazol como profilaxia de infecções fúngicas invasivas em receptores de transplante alogênico de células-tronco hematopoiéticas: experiência de um centro no Uruguai]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Prieto]]></surname>
<given-names><![CDATA[Jimena]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Figueroa]]></surname>
<given-names><![CDATA[Byron]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Irigoin]]></surname>
<given-names><![CDATA[Victoria]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Urrutia]]></surname>
<given-names><![CDATA[Romina]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Galeano]]></surname>
<given-names><![CDATA[Sebastián]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Oliver]]></surname>
<given-names><![CDATA[Carolina]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Riva]]></surname>
<given-names><![CDATA[Eloisa]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Perdomo]]></surname>
<given-names><![CDATA[Martina]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pierri]]></surname>
<given-names><![CDATA[Silvia]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Muxi]]></surname>
<given-names><![CDATA[Pablo]]></given-names>
</name>
</contrib>
</contrib-group>
<aff id="A">
<institution><![CDATA[,Hospital Británico  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<volume>41</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-03902025000101202&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-03902025000101202&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-03902025000101202&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: Las infecciones fúngicas invasivas (IFI) son una causa importante de morbi-mortalidad en los receptores de trasplante alogénico de células progenitoras hematopoyéticas (Alo-TCPH). Este estudio describe la experiencia de un único centro en Uruguay con el uso de voriconazol como profilaxis en los primeros 70 días post Alo-TCPH.  Objetivos: Describir la prevalencia de IFI, la tolerancia al voriconazol y los efectos adversos vinculados al mismo en pacientes receptores de Alo-TCPH.  Método: Estudio observacional prospectivo realizado en el Hospital Británico de Montevideo, Uruguay, entre el 5 de enero de 2022 y el 5 de junio de 2024. Se evaluó la población de pacientes que recibieron profilaxis con voriconazol.  Resultados: De 19 pacientes, 17 cumplieron los criterios de inclusión. La edad mediana fue de 57 años, y el 70,6% eran hombres. Ningún paciente desarrolló IFI. Todos mostraron buena tolerancia al voriconazol sin eventos adversos significativos. El 76,5% mantuvo niveles terapéuticos adecuados, mientras que el 23,5% presentó niveles por debajo del rango terapéutico, los cuales fueron ajustados exitosamente.  Conclusiones: El uso de voriconazol como profilaxis en pacientes receptores de Alo-TCPH mostró una buena tolerancia y efectividad en la prevención de IFI en nuestro centro.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Invasive fungal infections (IFI) are a significant cause of morbidity and mortality in recipients of allogeneic hematopoietic stem cell transplantation (Alo-HSCT). This study describes the experience of a single center in Uruguay with the use of voriconazole as prophylaxis during the first 70 days post Alo-HSCT.  Objectives: To describe the prevalence of IFI, the tolerance to voriconazole, and the associated adverse effects in Alo-HSCT recipients.  Method: A prospective observational study was conducted at the British Hospital of Montevideo, Uruguay, between January 5, 2022, and June 5, 2024. The patient population that received voriconazole prophylaxis was evaluated.  Results: Out of 19 patients, 17 met the inclusion criteria. The median age was 57 years, and 70.6% were male. No patients developed IFI. All showed good tolerance to voriconazole without significant adverse events. Therapeutic levels were adequate in 76.5% of cases, while 23.5% presented subtherapeutic levels that were successfully adjusted.  Conclusions: The use of voriconazole as prophylaxis in Alo-HSCT recipients demonstrated good tolerance and effectiveness in preventing IFI in our center.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução: As infecções fúngicas invasivas (IFI) são uma causa significativa de morbimortalidade em receptores de transplante alogênico de células-tronco hematopoéticas (Alo-TCPH). Este estudo descreve a experiência de um único centro no Uruguai com o uso de voriconazol como profilaxia nos primeiros 70 dias após o Alo-TCPH.  Objetivos: Descrever a prevalência de IFI, a tolerância ao voriconazol e os efeitos adversos associados ao seu uso em pacientes receptores de Alo-TCPH.  Método: Estudo observacional prospectivo realizado no Hospital Britânico de Montevidéu, Uruguai, entre 5 de janeiro de 2022 e 5 de junho de 2024. Foi avaliada a população de pacientes que receberam profilaxia com voriconazol.  Resultados: Dos 19 pacientes, 17 atenderam aos critérios de inclusão. A mediana de idade foi de 57 anos, e 70,6% eram homens. Nenhum paciente desenvolveu IFI. Todos mostraram boa tolerância ao voriconazol sem eventos adversos significativos. Níveis terapêuticos adequados foram mantidos em 76,5% dos casos, enquanto 23,5% apresentaram níveis abaixo do intervalo terapêutico, que foram ajustados com sucesso.  Conclusões: O uso de voriconazol como profilaxia em receptores de Alo-TCPH demonstrou boa tolerância e eficácia na prevenção de IFI em nosso centro.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Trasplante]]></kwd>
<kwd lng="es"><![CDATA[Alogénico]]></kwd>
<kwd lng="es"><![CDATA[Profilaxis]]></kwd>
<kwd lng="es"><![CDATA[Infección]]></kwd>
<kwd lng="es"><![CDATA[Fúngica]]></kwd>
<kwd lng="es"><![CDATA[Voriconazol]]></kwd>
<kwd lng="en"><![CDATA[Transplantation]]></kwd>
<kwd lng="en"><![CDATA[Allogeneic]]></kwd>
<kwd lng="en"><![CDATA[Prophylaxis]]></kwd>
<kwd lng="en"><![CDATA[Infection]]></kwd>
<kwd lng="en"><![CDATA[Fungal]]></kwd>
<kwd lng="en"><![CDATA[Voriconazole]]></kwd>
<kwd lng="pt"><![CDATA[Transplante]]></kwd>
<kwd lng="pt"><![CDATA[Alogênico]]></kwd>
<kwd lng="pt"><![CDATA[Profilaxia]]></kwd>
<kwd lng="pt"><![CDATA[Infecção]]></kwd>
<kwd lng="pt"><![CDATA[Fúngica]]></kwd>
<kwd lng="pt"><![CDATA[Voriconazol]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Pappas]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Challenges in management of invasive fungal infections in stem cell transplant]]></article-title>
<source><![CDATA[Transpl Infect Dis]]></source>
<year>2023</year>
<volume>25</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>e14175</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Towbin]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Schaefer]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Aria]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Towbin]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Invasive pulmonary aspergillosis]]></article-title>
<source><![CDATA[Appl Radiol]]></source>
<year>2020</year>
<volume>49</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>46-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shariati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Moradabadi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chegini]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Khoshbayan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Didehdar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An overview of the management of the most important invasive fungal infections in patients with blood malignancies]]></article-title>
<source><![CDATA[Infect Drug Resist]]></source>
<year>2020</year>
<volume>13</volume>
<page-range>2329-54</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="book">
<collab>Sociedad Argentina de Infectología</collab>
<source><![CDATA[Guía de recomendaciones 2023: Estrategias de prevención de infecciones en receptores de trasplante de células progenitoras hematopoyéticas]]></source>
<year>2023</year>
<publisher-loc><![CDATA[Buenos Aires ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad Argentina de Infectología]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wingard]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kurtzberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Small]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
<name>
<surname><![CDATA[Baden]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2010</year>
<volume>116</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>5111-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ullmann]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Aguado]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Arikan-Akdagli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Denning]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Groll]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Lagrou]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline]]></article-title>
<source><![CDATA[Clin Microbiol Infect]]></source>
<year>2018</year>
<page-range>24-38</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mellinghoff]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Panse]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Alakel]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Behre]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Buchheidt]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Christopeit]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)]]></article-title>
<source><![CDATA[Ann Hematol]]></source>
<year>2018</year>
<volume>97</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>197-207</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCreary]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Narayanan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Andes]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Cattaneo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Christian]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium]]></article-title>
<source><![CDATA[Pharmacotherapy]]></source>
<year>2023</year>
<volume>43</volume>
<numero>810</numero>
<issue>810</issue>
<page-range>1043-50</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mitterbauer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tobudic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kalhs]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rabitsch]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Greinix]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: A retrospective cohort study]]></article-title>
<source><![CDATA[BMC Infect Dis]]></source>
<year>2015</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cordonnier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sitbon]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Raus]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lortholary]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Maury]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mainly post-transplant factors are associated with invasive aspergillosis after allogeneic stem cell transplantation: a study from the surveillance des aspergilloses invasives en France and Société Francophone de Greffe de Moelle et de Thérapie Cellulaire]]></article-title>
<source><![CDATA[Biol Blood Marrow Transplant]]></source>
<year>2019</year>
<volume>25</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>354-61</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Talento]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Fitzgerald]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Redington]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Sullivan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fenelon]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention of healthcare-associated invasive aspergillosis during hospital construction/renovation works]]></article-title>
<source><![CDATA[J Hosp Infect]]></source>
<year>2019</year>
<volume>103</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marks]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Slavin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation]]></article-title>
<source><![CDATA[Expert Rev Anti Infect Ther]]></source>
<year>2017</year>
<volume>15</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>493-502</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trifilio]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pennick]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zook]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Golf]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kaniecki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2007</year>
<volume>109</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1532-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brüggemann]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maertens]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Van Eldere]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schulz]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Verweij]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of therapeutic drug monitoring of voriconazole in clinical practice: a prospective study]]></article-title>
<source><![CDATA[Ther Drug Monit]]></source>
<year>2009</year>
<volume>31</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>463-71</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valenzuela]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Salas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gajardo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Palma]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Catalán]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug interaction of voriconazole-cyclosporine in children undergoing hematopoietic stem cell transplantation (2013-2014)]]></article-title>
<source><![CDATA[Rev Chil Infectol]]></source>
<year>2017</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pasqualotto]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Xavier]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
<name>
<surname><![CDATA[Denning]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Variability in the pharmacokinetics of oral antifungal agents and its clinical implications]]></article-title>
<source><![CDATA[Curr Infect Dis Rep]]></source>
<year>2010</year>
<volume>12</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>440-6</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veringa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gubbels]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Danhof]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sturkenboom]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Kosterink]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Brüggemann]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Voriconazole metabolism, efficacy and toxicity: from theory to reality]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2016</year>
<volume>55</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>657-81</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ashbee]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Barnes]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Richardson]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Gorton]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hope]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic monitoring of antifungal agents: guidelines from the British Society for Medical Mycology]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2014</year>
<volume>69</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1162-76</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Andrews]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Charnot-Katsikas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Knox]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Buch]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fielden]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Isavuconazole and voriconazole for aspergillosis: a comparison of clinical outcomes and adverse events]]></article-title>
<source><![CDATA[Open Forum Infect Dis]]></source>
<year>2021</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
